Arvinas ARVN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arvinas in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arvinas's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arvinas's business segments — R&D?
- Arvinas (ARVN) reported business segments — R&D of $60.3M in Q1 2026.
- How has Arvinas's business segments — R&D changed year-over-year?
- Arvinas's business segments — R&D decreased by 33.6% year-over-year, from $90.8M to $60.3M.
- What is the long-term trend for Arvinas's business segments — R&D?
- Over 3 years (2022 to 2025), Arvinas's business segments — R&D has grown at a -3.3% compound annual growth rate (CAGR), from $315M to $285.2M.
- What does business segments — R&D mean?
- This represents the total investment made by the segment into the discovery and development of new therapeutic candidates. It is a critical measure of the company's commitment to innovation and its long-term pipeline potential.